What’s with All the Bio M&A in 2019?: A Quick Take
February 28, 2019
3,610
51
4
1.52%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
A16z Episodes Around February 28, 2019
See what was published immediately before and after this episode.
21:21Now PlayingWhat’s with All the Bio M&A in 2019?: A Quick Take
YouTube Description
as posted by the channelM&A in the biotech industry is off to a fast start in 2019. Just this past weekend, Roche announced it is acquiring Spark Therapeutics; Ipsen announced its acquisition of Clementia Pharma; and GE announced a spinoff of its biopharma business to Danaher.
Is this all just coincidence... or are there bigger trends at play? In this a16z hallway-style quick-take on recent news, a16z partners Kouki Harasaki (in bio go-to-market) and Nate Chang (in bio corporate development) chat with a16z operating partner Frank Chen about why all this M&A activity is happening now, and what it means for the bio startup ecosystem overall.
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.